Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial

Fig. 1

REFRACT trial schema. REFRACT trial schema showing the sequential three rounds of novel therapies (R1–3) which will be randomised and compared with investigator choice of standard therapy (ICT) in a ratio of 1:1 in R1 and 1:4 in favour of the novel therapy in R2 and R3. Patients receiving novel therapies in R2 and R3 will be compared with those patients who receive ICT in R1 and 2, or R1, R2, and R3, respectively. * Stratified by planned treatment regimen, consolidation intention, risk score, and number of lines of prior therapy. AEs, adverse events; CMR, complete metabolic response; ICT, Investigator choice of standard therapy; MTV, metabolic tumour volume; pts, patients; ORR, overall response rate; OS, overall survival; QoL, quality of life; R, round; TME, tumour microenvironment

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us